Loading
Alzheimer Disease / Alzheimer’s Disease · Journal article
Brain Research · June 19, 2026
Early or partial results. Treat as a signal, not a conclusion.
This in vitro study demonstrates that Aβ1-42 oligomers, but not Aβ1-40, induce cytotoxicity in oligodendrocyte precursor cells and pericytes while impairing endothelial barrier function through both direct and paracrine mechanisms. The findings provide mechanistic insight into potential BBB dysfunction in Alzheimer's disease, but require in vivo validation before clinical relevance can be established.
In vitro experimental study with cell culture and transcriptomic profiling. Oligodendrocyte precursor cells, pericytes, and endothelial cells cultured in vitro. Intervention: Aβ1-42 oligomers and Aβ1-40 exposure. Compared with: Untreated control cells (implied by comparison of Aβ1-42 and Aβ1-40 effects).
Aβ1-42, but not Aβ1-40, induced cytotoxicity in OPCs and PCs ECs showed impaired barrier function without cell death following Aβ1-42 exposure Aβ1-42-treated OPCs upregulated pro-inflammatory genes (Mmp9, Il1b) and downregulated genes related to cell cycle and growth signaling
Aβ1-42, but not Aβ1-40, induced cytotoxicity in OPCs and PCs
These findings suggest a potential mechanism linking Aβ1-42 to BBB dysfunction in Alzheimer's disease through effects on multiple cell types. However, clinicians should await in vivo validation before integrating these mechanisms into diagnostic or therapeutic strategies.
In vitro mechanistic study demonstrating Aβ1-42 effects on glial and vascular cells; lacks in vivo validation and clinical outcome data, limiting immediate translational impact.
As stated by the source record.
Quoted from the source exactly as published.
These findings suggest a potential mechanism linking Aβ1-42 to BBB dysfunction in Alzheimer's disease through effects on multiple cell types. However, clinicians should await in vivo validation before integrating these mechanisms into diagnostic or therapeutic strategies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Amyloid-β (Aβ), particularly the aggregation-prone Aβ1-42, plays a central role in Alzheimer's disease (AD). While its neuronal toxicity is well known, effects on glial and vascular cells remain unclear. To investigate how Aβ1-42 oligomers affect oligodendrocyte precursor cells (OPCs), pericytes (PCs), and endothelial cells (ECs), and how these effects contribute to blood-brain barrier (BBB) dysfunction. In vitro assays were used to assess cell viability and BBB integrity following Aβ exposure. Transcriptomic profiling was performed on Aβ1-42-treated OPCs. Transendothelial electrical resistance (TEER) was used to measure barrier function. Aβ1-42, but not Aβ1-40, induced cytotoxicity in OPCs and PCs. ECs showed impaired barrier function without cell death. Aβ1-42-treated OPCs upregulated pro-inflammatory genes (Mmp9, Il1b) and downregulated genes related to cell cycle and growth signaling. Conditioned media from Aβ-exposed OPCs and PCs reduced TEER in ECs, indicating paracrine-mediated BBB disruption. These findings demonstrate that Aβ1-42 oligomers impair BBB integrity under in vitro conditions through both direct and non-cell autonomous mechanisms. Further in vivo studies are warranted to validate the relevance of these mechanisms in AD pathogenesis.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.